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Background and aims: Familial hypobetalipoproteinemia (FHBL) is a co-dominant disorder characterized
by decreased plasma levels of LDL-cholesterol and apolipoprotein B (ApoB). Currently, genetic diagnosis
in FHBL relies largely on Sanger sequencing to identify APOB and PCSK9 gene mutations and on western
blotting to detect truncated ApoB species.
Methods: Here, we applied targeted enrichment and next-generation sequencing (NGS) on a panel of
three FHBL genes and two abetalipoproteinemia genes (APOB, PCSK9, ANGPTL3, MTTP and SAR1B).
Results: In this study, we identiﬁed ﬁve likely pathogenic heterozygous rare variants. These include four
novel nonsense mutations in APOB (p.Gln845*, p.Gln2571*, p.Cys2933* and p.Ser3718*) and a rare variant
in PCSK9 (Minor Allele Frequency <0.1%). The affected family members tested were shown to be carriers,
suggesting co-segregation with low LDL-C.
Conclusions: Our study further demonstrates that NGS is a reliable and practical approach for the mo-
lecular screening of FHBL-causative genes that may provide a mean for deciphering the genetic basis in
FHBL.
© 2016 Published by Elsevier Ireland Ltd.1. Introduction
Familial hypobetalipoproteinemia (FHBL) belongs to a hetero-
geneous group of monogenic disorders characterized by reduced
plasma levels of low-density lipoprotein cholesterol (LDLC) and
apolipoprotein B (ApoB) below the ﬁfth percentile for age and sex
in the population. FHBL is a co-dominant disorder whose frequencyl'Institut du Thorax, Ho^pital
, 44093 Nantes cedex, France.
MR6291, L'institut du thorax,
dex 1, France.
hott), bertrand.cariou@univ-in the heterozygous form is estimated to be 1:1000e1:3000 [1,2].
FHBL heterozygotes may be asymptomatic or have some clinical
manifestations such as liver steatosis. Furthermore, FHBL has been
associated with a longevity syndrome linked to cardiovascular
protection [1,2]. FHBL is genetically heterogeneous and may be due
to loss-of-function mutations in APOB [1,2], or less frequently in
PCSK9, which encodes the proprotein convertase subtilisin/kexin
type 9 [3e5]. In addition, familial combined hypolipidemia - which
is characterized by low levels of LDL-C, high-density lipoprotein
cholesterol (HDL-C) and triglycerides (TG) can be caused by mu-
tations in the angiopoietin-like 3 gene (ANGPTL3) [6,7]. Despite
previous gene discoveries, the genetic etiology of FHBL remains to
be determined in approximately 50% of cases [1,8].
Currently, genetic diagnosis in FHBL relies largely on Sanger
A. Rimbert et al. / Atherosclerosis 250 (2016) 52e56 53sequencing of APOB. Because APOB is a large gene composed of 29
exons covering 14,121 bp, Western-blotting may be used to detect
truncated protein species that are >30% of full-length protein size
[1,2]. When Western blotting is negative, sequencing the 25 ﬁrst
exons of APOB gene (exons 1 to 25) - a time consuming and costly
approach - is mandatory [9,10]. Next-generation sequencing (NGS)
technologies enable rapid and cost-effective sequencing of targeted
genomic regions. NGS is thus a powerful approach for genetic di-
agnostics in inherited Mendelian disorders [11,12]. In the present
study, we developed a targeted resequencing panel to screen for
coding variations amongst three known FHBL and two abetalipo-
proteinemia (ABL) genes. Re-sequencing these genes in eight un-
related individuals with FHBL revealed four novel missense
mutations in APOB that segregatewith the low LDL-C trait in related
individuals as well as one likely pathogenic mutation in PCSK9.
2. Patients and methods
2.1. Study approval
The study (NCT02354079) was conducted in compliance with
current Good Clinical Practice standards. We obtained informed
consent from individuals involved in the study and approval from
local institutional ethics committees (CPP OUEST IV 49/14).
2.2. Patient recruitment and clinical evaluation
Eight unrelated individuals routinely followed for FHBL in the
department of endocrinology at Nantes University Hospital have
been recruited. In the probands, FHBL diagnosis was based on low
levels of fasting calculated plasma LDL-C < 50 mg/dL without lipid
lowering therapy. Fasting lipid proﬁle (total cholesterol, HDL-C,
LDL-C and TG) and ApoB levels were also determined in some of
their relatives. Affected relatives were diagnosed by LDL-C < 80mg/
dL and/or ApoB <50mg/dL. Anthropometric data, biochemical tests
and abdominal ultrasonography were recorded.
2.3. Capture design and library preparation
We developed a re-sequencing custom design based on the
HaloPlex™ Target Enrichment system (Agilent Technologies) to
perform high-throughput sequencing of the coding regions of
genes previously linked to FHBL (APOB, PCSK9, ANGPTL3) and ABL
(MTTP, SAR1B) encoding the Microsomal Triglyceride Transfer Pro-
tein and the Secretion Associated, Ras related GTPase 1B, respec-
tively). Targeted coding regions (exons þ about 10-bp non coding
ﬂanking sequences) correspond to 22.83 kb of genomic sequence.
Sequencing (100-bp paired-end reads) was performed on Illumina
HiSeq 2500 station.
2.4. Variant calling and ﬁltering
Raw sequence reads were aligned to the human reference
genome (GRCh37) using BWA-MEM (version 0.7.5a) after removing
sequences corresponding to Illumina adapters with Cutadapt (v1.2).
Variants were called for each sample separately using GATK Uni-
ﬁedGenotyper (version 2.8) and Samtools mpileup (version 0.1.19):
they were considered for further analyses when found by both al-
gorithms. Variants frequency was determined using the Exome
Aggregation Consortium database (Exac.broadinstitute.org/): they
were considered as rare when the minor allele frequency (MAF)
was lower than 0.1% in the non-Finnish European population. The
potential effect of variants was determined using Variant Effect
Predictor annotations (Ensembl). Filtering was performed using
Knime4Bio [13].2.5. Validation (visualization and Sanger sequencing)
All relevant variants identiﬁed in the eight patients were
reviewed by visual inspection of sequence reads using the Inte-
grative Genomics Viewer [14]. Sanger sequencing was performed
for validation and co-segregation analysis among family members.
Regions of interest were ampliﬁed by polymerase chain reaction
and sequenced with the dye-terminator chemistry (ABI PRISM
3730, Applied Biosystems, Foster City, CA).
2.6. Dosage of lipoproteins in plasma
Plasma levels of ApoA-I, ApoA-II, ApoB-100, ApoC-II, ApoC-III,
ApoE and Lp(a) were measured using the multiplexed LC/MS/MS
method as previously described [15].
2.7. Lipoprotein separation and ApoB western blotting
The LDL plasmatic fractions were obtained by ultracentrifuga-
tion separation protocol [16]. 50 mg of extracted proteins were
separated by SDS-PAGE and transferred to a nitrocellulose mem-
brane. Immunoblots probed with polyclonal antibody ApoB-100
(AB742) (1:1000) and HRP-conjugated antibodies (rabbit anti-
goat IgG-HRP: sc-2768) (1:10,000) were purchased from Merck
Millipore and Santa-Cruz biotechnology respectively.
3. Results
3.1. Targeted resequencing
Eight patients followed for FHBL in our clinical department have
been included in this study. Their plasma lipid panels are listed in
the Supplemental Table 1. Five genes were sequenced using the
custom capture design that we developed based on the HaloPlex™
technology. The mean coverage depth was 201X (±90) per sample
with 98% of the target regions being covered at least 10 times (96.1%
covered at least 20 times). Mean coverage depths throughout the
ﬁve target genes are shown in Supplemental Fig. 1.
We identiﬁed ﬁve heterozygous rare variants (MAF < 0.1%) that
alter ApoB or PCSK9 protein sequence. The four APOB variants
(p.Gln845*, p.Gln2571*, p.Cys2933* and p.Ser3718*) are likely
pathogenic nonsense variants (SO: 0001587 stop gained) that are
absent from the ExAC database.
The PCSK9-c.523 G > A variant was reported twice in the ExAC
database (65,770 non-Finnish European population alleles). Pre-
dicted functional consequences of this variant either lead to: -a
PCSK9 p.Asp175Asn missense variant (SO: 0001583) respectively
annotated as tolerated or benign by SIFT/PolyPhen algorithms and
displaying low conservation scores (CADD score ¼ 0.226944 and
GERP score¼1.33) or to -a splice variant (SO: 0001630), that leads
to a frameshift followed by a premature stop codon PCSK9-
p.Asp175Serfs*13.
No variant was identiﬁed in the three other targeted genes ac-
cording to our ﬁltering criteria.
3.2. Identiﬁed variants co-segregate with FHBL
Segregation analysis of the APOB variants were performed in
proband's family members when available (Fig. 1). Patients' clinical
and biological characteristics are reported in Table 1.
The ﬁrst APOB variant (Chr2:21,246,468; c.2533G > A; APOB-
p.Gln845*) was identiﬁed in a 49 years-old woman (II:2/Family I)
presenting low LDL-C (20 mg/dL). The proband's sons (III:1 and
III:2) who had low LDL-C levels harbor the mutation. The youngest
boy (III:2) also exhibited hepatic steatosis without increased liver
Fig. 1. Pedigrees and mutations. Upper panels: Pedigrees. Arrows indicate index cases. Female are identiﬁed by circles and males by squares. FHBL affected individuals are
indicated by ﬁlled symbols, unaffected individuals by empty symbols and individuals with unknown cholesterol phenotype by (?). Heterozygous mutations are designated M, and
the wild-type sequence WT. Lower panels: Sanger sequencing chromatograms showing the heterozygous APOB mutations (A) and the PCSK9 variant (B). C-APOB p.Cys2933* and
p.Ser3718* mutations generate circulating truncated proteins. Western-blot was performed with lipoprotein plasmatic fractions from APOB-mutated patients on a 6% acrylamide gel
with a short migration time (left panel) or on a 5% acrylamide gel with a long migration time to discriminate high molecular forms (right panel). All samples present a secreted WT-
ApoB form (ApoB-100: 515 kDa) in the plasma (black arrows) as seen in the patient carrying the PCSK9 variant (PCSK9-c.593 G > A) taken as a control. No truncated forms of ApoB
were identiﬁable for ApoB-18 (p.Gln845*:94 kDa) and ApoB-56 (p.Gln2571*: 289 kDa). The truncated forms ApoB-64 (p.Cys2933*: 330 kDa) and ApoB-81 (p.Ser3718*: 418 kDa) are
visible (red arrow) at the expected molecular weights.
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presented normal LDL-C levels. Interestingly, the proband's
paternal grandfather died late in life (>95 years), potentially sug-
gesting a longevity syndrome as previously described in FHBL [1,2].
The second APOB variant (Chr2:21,232,029; c.7711G > A; APOB-
p.Gln2571*) was identiﬁed in a 41 years-old man (II:1/Family II)
who had low LDL-C (38 mg/dL), pre-diabetes and liver steatosis.
DNA from his family was not available for segregation analyses.
The third APOB variant (Chr2:21,230,941; c.8799 G > T; APOB-
p.Cys2933*) was identiﬁed in a 24 years-old woman (II:2/Family III)
who showed low LDL-C (28 mg/dL). Her mother (I:2) and sister(II:1) also had low LDL-C. The proband's mother harbor the APOB-
p.Cys2933* variant.
The fourth APOB variant (Chr2:21,228,587; c.11153 G > C; APOB-
p.Ser3718*) was identiﬁed in an 84 years-old man (I:1/Family IV)
who showed a low LDL-C level (33 mg/dL). The three other affected
members of the family, his son (II:1) and great-children (III:1 and
III:2) with low LDL-C levels harbor the APOB-p.Ser3718* variant.
Subject II-1 also had type 2 diabetes and severe non-alcoholic
steatohepatitis (NASH) with precirrhotic lesions and well-
differentiated hepatocellular carcinoma (HCC) diagnosed on liver
biopsy.
Table 1
Main biological features and mutations of FHBL family members.
Age Gender BMI Diabetes TC (mg/
dL)
LDL-C (mg/
dL)
HDL-C (mg/
dL)
TG (mg/
dL)
FPG
(mmol/L)
HbA1C
(%)
AST
(ULN)
ALT
(ULN)
GGT
(ULN)
ALP
(ULN)
Liver
steatosis
Molecular
alteration
Family I
I:1 83 M n.a. n.a. n.a. 58 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
II:1 51 M n.a. n.a. 207 135 51 102 n.a. n.a. 0.52 0.64 0.35 0.71 n.a. WT
II:2 49 F 20 No 143 20 120 18 4.7 5.0 0.66 0.74 0.38 0.39 N APOB-
p.Gln845*
II:3 48 M n.a. n.a. 230 155 52 117 n.a. n.a. n.a. n.a. n.a. n.a. n.a. WT
III:1 17 M 18 No 98 14 79 25 n.a. n.a. 0.40 0.32 0.42 0.37 n.a. APOB-
p.Gln845*
III:2 15 M 18 No 104 7 91 31 n.a. n.a. 0.55 0.46 0.30 0.63 Y APOB-
p.Gln845*
Family II
II:1 40 M 34 Prediabetes 113 38 69 32 7.2 5.9 0.8 1.34 0.47 0.36 Y APOB-
p.Gln2571*
Family III
I:2 61 F 24 No 145 55 81 45 4.9 5.9 1.08 1.03 0.55 0.54 n.a. APOB-
pCys2933*
II:1 39 F n.a. n.a. 166 17 147 12 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
II:2 24 F 27 No 143 28 110 26 4.2 n.a. 0.88 1.00 0.88 1.01 n.a. APOB-
pCys2933*
Family IV
I:1 84 M 26 No 106 33 60 60 4.7 n.a. 0.62 0.42 1.44 0.50 Y APOB-
p.Ser3718*
II:1 58 M 34 Yes 123 40 68 75 7.2 6.5 2.34 2.26 11.73 0.47 Ya APOB-
p.Ser3718*
II:2 58 F n.a. No 250 142 98 50 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
III:1 26 M 21 No 102 36 57 46 n.a. 5.4 0.46 0.74 0.34 0.23 n.a. APOB-
p.Ser3718*
III:2 18 F 19 No 124 49 62 65 n.a. n.a. n.a. n.a. n.a. n.a. N APOB-
p.Ser3718*
Family V
I:2 52 F 22 No 132 63 55 72 n.a. 5.5 0.54 0.37 0.33 0.56 n.a. PCSK9-
c.523G > A
II:1 23 M 22 No 120 50 55 89 4.5 n.a. 0.53 0.29 0.18 n.a. n.a. PCSK9-
c.523G > A
II:2 16 M 20 No 141 74 52 76 4.3 n.a. 1.05 0.54 0.41 0.32 n.a. PCSK9-
c.523G > A
II:3 13 F n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a n.a PCSK9-
c.523G > A
Age is expressed in years; body mass index (BMI) in kg/m2, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C),
triglycerides (TG) in mg/dL; fasting plasma glucose (FPG) in mmol/L; glycated hemoglobin (HbA1c) in %; transaminases (aspartate aminotransferase (AST) and alanine
aminotransferase (ALT), alkalin phosphatase (ALP), and gamma glutamyl transferase (GGT), are expressed in upper limits of normal (ULN). Amino acid designation begins with
“1” at translation start codon 129 of APOB cDNA (Genbank entry NM_000384.2); F, female; M, male; WT, wild-type sequence; n.a., not available.
a Hepatocellular carcinoma.
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identiﬁed in a 23 years-old man (II:1/Family V) with low LDL-C
level (50 mg/dL). The proband's mother (I:2) and brother (II-2)
who also had low LDL-C (63 mg/dL and 74 mg/dL respectively)
harbor the variant. The proband's sister (II:3) with unknown
phenotype also harbor the variant.
3.3. APOB-p.Cys2933* and p.Ser3718* mutations generate
circulating truncated proteins
APOB-p.Gln845* and p.Gln2571* mutations can potentially
generate truncated proteins with expected weight of 94 kDa and
289 kDa respectively. These truncated forms were not visible in
plasma (Fig. 1C). APOB-p.Cys2933* and p.Ser3718* mutations lead
to the formation of expected truncated ApoB forms (ApoB-64 and
ApoB-81) of 330 kDa and 418 kDa (Fig. 1C, right panel) that can be
secreted by the liver and lipidated.
4. Discussion
We have developed a targeted NGS approach to improve mo-
lecular diagnosis for FHBL. By testing this approach on a series of
eight FHBL probands, we identiﬁed four heterozygous likelydisease-causing APOB nonsense mutations. Our 50% detection rate
for APOB mutation is in line with previously reported APOB muta-
tion prevalence in FHBL patients [8,1]. Liver steatosis was diagnosed
in four patients from three families with APOBmutations, including
one with severe NASH complicated by a HCC, reinforcing the hy-
pothesis that some APOB mutations could lead to FHBL, liver
cirrhosis and HCC [17]. We also identiﬁed a rare PCSK9-c.523 G > A
variant that co-segregates with FHBL. Although in silico analyses
predict a potential PCSK9 splice variant, further functional experi-
ments are needed to determine whether this variant is associated
with a PCSK9 loss-of-function.
APOB encodes a product containing 4563 amino acids and en-
compasses 29 exons. Over 90 mutations have been reported in
subjects with FHBL, mostly nonsense and frameshift mutations and
novel mutations are continually being identiﬁed. Moreover,
missense mutations have been described in FHBL [18,19] and could
be missed by current genetic testing using western-blotting as a
ﬁrst-line approach. Because most unrelated FHBL kindreds carry
private mutations and because there is no evidence for FHBL mu-
tation hotspots, further development of reliable, high throughput
and cost effective molecular screening approaches are needed. In
the context of genetically heterogeneous diseases involving large
genes, targeted resequencing technology has become an accurate,
A. Rimbert et al. / Atherosclerosis 250 (2016) 52e5656fast and cost effective approach, which is applicable in routine
molecular clinical diagnosis [20,21]. Johansen et al. recently
designed a large targeted resequencing panel to investigate 73
genes in patients presenting various forms of dyslipidemia and
related metabolic disorders [12]. They demonstrated that - despite
some limitations due to lower coverage depth for particular
genomic regions and to the nondetection of genome structural
variation - this panel allows the detection of most known muta-
tions based on Sanger sequencing as well as high detection rates for
coding mutations in previously unsequenced samples.
Interestingly, the patients carrying no disease-relevant variant
in the known FHBL-susceptibility genes could be subjected to
whole exome sequencing combined with exhaustive familial
investigation, in order to identify new disease genes. The demon-
stration that PCSK9 loss-of-function mutations are associated with
reduced cardiovascular events [22] has been the accelerator for the
development of PCSK9 inhibitors. More recently, monoclonal an-
tibodies directed against ANGTPL3 have demonstrated lipid-
lowering efﬁcacy in monkeys [23]. In this context, comprehensive
genetic resequencing ranging from exome to whole genome but
also RNA sequencing could represent the ﬁrst step towards iden-
tifying new drug targets in hypercholesterolemia.
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